Jay Levine, DPM
Podiatrist · Nanuet, NYNPI 1366473845
Payments from drug & device makers
Across 55 payments — averaging $26.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$242
- Amgen$180
- Corcept Therapeutics$170
- Smith+Nephew$151
- Abbott$114
- Crossroads Extremity Systems, LLC$93
- plus $502 from 17 others
What the payments were for
- Food & beverage$1,451100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 7 | $242 |
| Amgen | 10 | $180 |
| Corcept Therapeutics | 6 | $170 |
| Smith+Nephew | 2 | $151 |
| Abbott | 5 | $114 |
| Crossroads Extremity Systems, LLC | 1 | $93 |
| Mannkind Corporation | 2 | $92 |
| Novo Nordisk | 2 | $45 |
| Verity Pharmaceuticals Inc. | 2 | $39 |
| IBSA Pharma Inc. | 2 | $37 |
| Recordati_rare_diseases_inc. | 2 | $35 |
| Antares Pharma, Inc. | 2 | $33 |
| Merck | 2 | $26 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Radius Health, Inc. | 1 | $21 |
| Bayer | 1 | $20 |
| Exact Sciences | 1 | $20 |
| EUSA Pharma (US) LLC | 1 | $20 |
| Neurocrine Biosciences, Inc. | 1 | $18 |
| Alvogen Inc | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $17 |
| Averitas Pharma Inc. | 1 | $16 |
How this compares
$1,451 in reported general payments places this provider in the 65th percentile of 862 podiatrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JubliaEfinaconazole | 26 | $33,347 |
| CiclopiroxCiclopirox Olamine | 139 | $2,705 |
| Ketoconazole | 123 | $2,617 |
| Mupirocin | 226 | $1,388 |
| Colchicine | 44 | $1,099 |
| Silver Sulfadiazine | 35 | $377 |
| Ciclopirox | 14 | $237 |
| Cephalexin | 52 | $221 |
| SsdSilver Sulfadiazine | 20 | $182 |
| Doxycycline Hyclate | 23 | $150 |
Paid to pharmacies, not to this prescriber.
Other podiatrist in Nanuet
- Christopher BromleyPoughkeepsie$152K
- Scott GawlikBrooklyn$77K
- Waldemar MajdanskiAstoria$71K
- Michael HutzelSeaford$64K
- Donald RubinCorning$53K
- Steven NormanMiddle Village$42K
- Elvis DanneNew York$35K
- Adam CirlincioneGlen Cove$31K
- Jude ViolanteNiagara Falls$30K
- Ammar Al RubaiayNew Hyde Park$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.